Drug intelligence / Profile preview

IDB002

Development stage: Preclinical
Lead developer: IDBiologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

IDB002 is a human monoclonal antibody developed by IDBiologics as an ultra-potent neutralizing agent for infectious diseases. It is being investigated primarily for pre-exposure prophylaxis (PrEP) against Zika virus (ZIKV) infection, with demonstrated neutralizing activity and protection in animal models including pregnant mice and non-human primates. Additionally, some sources describe it as a monoclonal antibody targeting the respiratory syncytial virus (RSV) F protein for the prevention or treatment of RSV infections. The drug is currently in preclinical or discovery stages and has not yet reached clinical approval[1][2][4].

Targets

RSV F (Respiratory syncytial virus fusion protein)ZIKV E (Zika virus envelope protein)

Beyond the preview

Go deeper on IDB002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDB002.

Explore the full profile